FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065614359> ?p ?o ?g. }

• W2065614359 endingPage "97" @default.
• W2065614359 startingPage "87" @default.
• W2065614359 abstract "Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. However, the clinical and virological long-term outcome of HDV-infected patients treated with PEG-IFNa is unknown. We performed a retrospective-prospective follow-up of 77 patients treated for 48 weeks with either PEG-alfa-2a and adefovir (ADV) or either drug alone in the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-1) trial. Long-term follow-up data were available for 58 out of 77 patients (75%) with a median time of follow-up of 4.5 (0.5-5.5) years and a median 3 visits per patient. Patients treated with ADV alone received retreatment with PEG-IFNa (48% versus 19%; P = 0.02) more often. Hepatitis B virus surface antigen (HBsAg) became negative in six PEG-IFNa-treated patients until the end of long-term follow-up (10%). Sixteen patients tested HDV RNA-negative 6 months after PEG-IFNa treatment who were entered in the long-term follow-up study. Out of these, nine individuals tested HDV RNA-positive at least once during further long-term follow-up, with seven patients being HDV RNA-positive at the most recent visit. Clinical endpoints (liver-related death, liver transplantation, hepatic decompensation, hepatocellular carcinoma) were observed in three PEG-IFNa-treated (8%) and three ADV-treated (14%) patients during posttreatment long-term follow-up with an overall annual event rate of 2.5% (4.9% in cirrhosis). Sequencing confirmed the reappearance of pretreatment virus strains in all cases. Conclusion: Late HDV RNA relapses may occur after PEG-IFNa therapy of hepatitis delta and thus the term sustained virological response should be avoided in HDV infection. The annual posttreatment rate of clinical events in hepatitis delta patients eligible for PEG-IFNa therapy is about 2.5% and 4.9% in patients with cirrhosis. (Hepatology 2014;60:87-97)" @default.
• W2065614359 created "2016-06-24" @default.
• W2065614359 creator A5002183557 @default.
• W2065614359 creator A5006198673 @default.
• W2065614359 creator A5009238813 @default.
• W2065614359 creator A5010614894 @default.
• W2065614359 creator A5012052658 @default.
• W2065614359 creator A5019174432 @default.
• W2065614359 creator A5024581579 @default.
• W2065614359 creator A5045504446 @default.
• W2065614359 creator A5048319836 @default.
• W2065614359 creator A5061759237 @default.
• W2065614359 creator A5070174845 @default.
• W2065614359 creator A5076739762 @default.
• W2065614359 creator A5077245179 @default.
• W2065614359 creator A5078233510 @default.
• W2065614359 creator A5088189620 @default.
• W2065614359 creator A5088602858 @default.
• W2065614359 date "2014-06-26" @default.
• W2065614359 modified "2023-10-16" @default.
• W2065614359 title "Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta" @default.
• W2065614359 cites W1559090356 @default.
• W2065614359 cites W1814037092 @default.
• W2065614359 cites W1935883683 @default.
• W2065614359 cites W1966807894 @default.
• W2065614359 cites W1977020122 @default.
• W2065614359 cites W1980154502 @default.
• W2065614359 cites W1985437256 @default.
• W2065614359 cites W1986388698 @default.
• W2065614359 cites W1986988924 @default.
• W2065614359 cites W1991612900 @default.
• W2065614359 cites W2001497311 @default.
• W2065614359 cites W2007235791 @default.
• W2065614359 cites W2009089135 @default.
• W2065614359 cites W2009474584 @default.
• W2065614359 cites W2011951516 @default.
• W2065614359 cites W2020963980 @default.
• W2065614359 cites W2026141298 @default.
• W2065614359 cites W2027032176 @default.
• W2065614359 cites W2029132988 @default.
• W2065614359 cites W2029529502 @default.
• W2065614359 cites W2031741228 @default.
• W2065614359 cites W2049497933 @default.
• W2065614359 cites W2060563877 @default.
• W2065614359 cites W2068797382 @default.
• W2065614359 cites W2071993332 @default.
• W2065614359 cites W2075820772 @default.
• W2065614359 cites W2076037594 @default.
• W2065614359 cites W2089153567 @default.
• W2065614359 cites W2090318501 @default.
• W2065614359 cites W2106014389 @default.
• W2065614359 cites W2108435608 @default.
• W2065614359 cites W2109935555 @default.
• W2065614359 cites W2115768654 @default.
• W2065614359 cites W2117766751 @default.
• W2065614359 cites W2133202656 @default.
• W2065614359 cites W2135222796 @default.
• W2065614359 cites W2140986191 @default.
• W2065614359 cites W2141448996 @default.
• W2065614359 cites W2149145826 @default.
• W2065614359 cites W2149782865 @default.
• W2065614359 cites W2159044251 @default.
• W2065614359 cites W2167673078 @default.
• W2065614359 cites W4211026375 @default.
• W2065614359 cites W4211077792 @default.
• W2065614359 doi "https://doi.org/10.1002/hep.27102" @default.
• W2065614359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24585488" @default.
• W2065614359 hasPublicationYear "2014" @default.
• W2065614359 type Work @default.
• W2065614359 sameAs 2065614359 @default.
• W2065614359 citedByCount "223" @default.
• W2065614359 countsByYear W20656143592014 @default.
• W2065614359 countsByYear W20656143592015 @default.
• W2065614359 countsByYear W20656143592016 @default.
• W2065614359 countsByYear W20656143592017 @default.
• W2065614359 countsByYear W20656143592018 @default.
• W2065614359 countsByYear W20656143592019 @default.
• W2065614359 countsByYear W20656143592020 @default.
• W2065614359 countsByYear W20656143592021 @default.
• W2065614359 countsByYear W20656143592022 @default.
• W2065614359 countsByYear W20656143592023 @default.
• W2065614359 crossrefType "journal-article" @default.
• W2065614359 hasAuthorship W2065614359A5002183557 @default.
• W2065614359 hasAuthorship W2065614359A5006198673 @default.
• W2065614359 hasAuthorship W2065614359A5009238813 @default.
• W2065614359 hasAuthorship W2065614359A5010614894 @default.
• W2065614359 hasAuthorship W2065614359A5012052658 @default.
• W2065614359 hasAuthorship W2065614359A5019174432 @default.
• W2065614359 hasAuthorship W2065614359A5024581579 @default.
• W2065614359 hasAuthorship W2065614359A5045504446 @default.
• W2065614359 hasAuthorship W2065614359A5048319836 @default.
• W2065614359 hasAuthorship W2065614359A5061759237 @default.
• W2065614359 hasAuthorship W2065614359A5070174845 @default.
• W2065614359 hasAuthorship W2065614359A5076739762 @default.
• W2065614359 hasAuthorship W2065614359A5077245179 @default.
• W2065614359 hasAuthorship W2065614359A5078233510 @default.
• W2065614359 hasAuthorship W2065614359A5088189620 @default.
• W2065614359 hasAuthorship W2065614359A5088602858 @default.

• next